TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN
https://doi.org/10.20996/1819-6446-2013-9-3-301-305
Abstract
Low dose aspirin reduces the secondary incidence of myocardial infarction and stroke. Drug resistance to aspirin might result in treatment failure. Despite this concern, no clear definition of aspirin resistance has emerged, and estimates of its incidence have varied remarkably. Researchers from university of Pennsylvania (Philadelphia, the USA), led by Dr. Tilo Grosser, aimed to determine the specific phenotype of true pharmacological resistance to aspirin — such as might be explained by genetic causes. However the study failed to identify a single case of true drug resistance. Pseudoresistance, reflecting delayed and reduced drug absorption, complicates enteric coated but not immediate release aspirin administration.
About the Authors
A. I. Martynov
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
E. V. Akatova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
I. V. Urlayeva
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
O. P. Nicolin
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow
Russian Federation
Russian Federation
References
1. Martin C.P., Talbert R.L. Aspirin Resistance: An evaluation of Current Evidence and Measurement Methods. Pharmacotherapy 2005; 25(7):942–953.
2. Hankey G.J., Eikelboom J.W. Aspirin resistance. Lancet 2006;367(9510):606–17.
3. Topol E.J., Easton D., Harrington R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406.
4. Bhatt D.L., Chew D.P., Hirsch A.T., et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363–368.
5. Chen W.H., Lee P.Y., Ng W., et al. Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol 2005;45:382A.
6. Bhatt D.L., Topol E.J. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am 2000;84:163–179.
7. Hostetter J.C., Bhatt D.L. The expanding role of Antiplatelet agents in coronary artery disease. Miner- va Cardioangiol 2003; 51:531–46.
8. Cipollone F., Rocca B., Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004;24(2):246–55.
9. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147(2):293–300.
10. Pulcinelli F.M., Pignatelli P., Celestini A., et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43(6):979–84.
11. Ray W.A., Stein C.M., Hall K., et al. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118–23.
12. Livio V., Delmaschio A., Cerletti C., deGaetano G. Indomethacin prevents long-lasting inhibitory effects of aspirin on human platelet cyclooxygenase. Prostaglandins 1982; 23:787–96.
13. MacDonald T.M., Wei L. Effect of ibuprofen on cardioprotecive effect of aspirin. Lancet 2003; 361:573–4.
14. Hurlen M., Seljeflot I., Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000;99(5):487–94.
15. Kawasaki T., Ozeki Y., Igawa T., Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591–5.
16. Grundmann K., Jaschonek K., Kleine B., et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250(1):63–6.
17. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78(3):1003– 7.
18. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natu- ral history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961–5.
19. Grosser T, Fries S, Lawson JA et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013;127(3):377–85.
20. Muir N., Nichols J.D., Clifford J.M., et al. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Res Opin 1997;13:547–553.
21. Bochner F., Somogyi A.A., Wilson K.M. Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 1991;21:394–399.
22. Maree A.O., Curtin R.J., Dooley M., et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–1263.
23. Cox D., Maree A.O., Dooley M., et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:2153–2158.
24. Peace A., McCall M., Tedesco T., et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–2325.
25. Reilly I.A., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180–186.
26. Patrono C., Ciabattoni G., Pinca E., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317–327.
27. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009;53:667–677.
28. Faraday N., Yanek L.R., Mathias R., et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490–2496.
29. Webster S.E., Payne D.A., Jones C.I., et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 2004;40:463–468.
30. Valles J., Santos M.T., Aznar J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350–355.
31. Folts J.D., Schafer A.I., Loscalzo J., et al. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999;33:295–303.
32. Mehta S.R., Yusuf S., Peters R.J., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–533.
33. Schwartz K.A., Schwartz D.E., Ghosheh K., et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973– 975.
34. Hennekens C.H., Schneider W.R., Hebert P.R., et al. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to «aspirin resistance». Am Heart J 2010;159:744–748.
35. Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603.
36. Rocca B., Santilli F., Pitocco D., et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220–1230.
37. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.
38. William H., John A. Collaborative overview of randomised trials of antiplatelet therapy: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet trialists’ collaboration. BMJ 1994;308:235–246. .
Review
For citations:
Martynov A.I., Akatova E.V., Urlayeva I.V., Nicolin O.P. TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN. Rational Pharmacotherapy in Cardiology. 2013;9(3):301-305. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-301-305
Views: 921
Email this article 